医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

ヘルス一般

LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer

LYNPARZA® (olaparib) Approved in China as a First-Line Maintenance Therapy in BRCA-Mutated (BRCAm) Advanced Ovarian Cancer

バイオテクノロジーヘルスケアヘルス一般腫瘍学臨床試験製薬遺伝学　 TimeLine: Advanced Ovarian Cancer Approved in China as a First-Line Maintenance

2019年12月05日

OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

OncoSec Comments on Disturbing Elements of Alpha Holdings’ Revised Preliminary Proxy Filing

ヘルスケアヘルス一般腫瘍学　 TimeLine: OncoSec Comments on Disturbing Elements of Alpha Revised Preliminary Proxy Filing

2019年12月04日

Nanomix Receives CE Mark for Diagnostic Panel That Aids in Rapid Identification of Serious, Life-Threatening Infections

Nanomix Receives CE Mark for Diagnostic Panel That Aids in Rapid Identification of Serious, Life-Threatening Infections

その他ヘルスバイオテクノロジーヘルスケアヘルス一般医療機器感染症病院　 TimeLine: Life-Threatening Infections Nanomix Receives CE Mark for Diagnostic Panel

2019年12月04日

Dr. Reddy’s Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

Dr. Reddy’s Laboratories Announces the Launch of Bortezomib for Injection 3.5 mg/vial for Intravenous Use Only in the U.S. Market

ヘルスケアヘルス一般病院腫瘍学製薬　 TimeLine: Reddy's Laboratories Announces the Launch vial for Intravenous Use Only in the

2019年12月04日

Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.

Brii Biosciences Expands Therapeutic Focus to Include Neurosciences with Addition of John Kraus, M.D., Ph.D.

バイオテクノロジーヘルスケアヘルス一般感染症臨床試験製薬　 TimeLine: Brii Biosciences Expands Therapeutic Focus

2019年12月03日

Co-Diagnostics JV CoSara Receives Indian Regulatory Approval for Five Diagnostic Assays

Co-Diagnostics JV CoSara Receives Indian Regulatory Approval for Five Diagnostic Assays

AIDS ヘルスケアヘルス一般感染症遺伝学　 TimeLine: Co-Diagnostics JV CoSara Receives Indian

2019年12月03日

Pharmaron Lists H-Shares on the Hong Kong Stock Exchange

Pharmaron Lists H-Shares on the Hong Kong Stock Exchange

バイオテクノロジーヘルスケアヘルス一般製薬　 TimeLine: Pharmaron Lists H-Shares on the Hong Kong

2019年11月28日

Alipay’s Xiang Hu Bao Online Mutual Aid Platform Attracts 100 Million Participants in One Year

Alipay’s Xiang Hu Bao Online Mutual Aid Platform Attracts 100 Million Participants in One Year

その他ヘルスヘルスケアヘルス一般マネージド・ケア病院　 TimeLine: Alipay's Xiang Hu Bao Online Mutual Aid

2019年11月27日

Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

Merck’s KEYTRUDA® (pembrolizumab) Now Approved in China for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) in Combination with Chemotherapy

バイオテクノロジーヘルスケアヘルス一般製薬　 TimeLine: in Combination with Chemotherapy Merck's KEYTRUDA Now Approved in China for First-Line Treatment pembrolizumab

2019年11月26日